# US 2026/0234663 A1 · Recombinant viral vector and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234663 A1
- Document ID: US20260234663A1
- Status: Published application
- Kind: A1
- Application number: 19/460,532
- Filed: 2026-01-27
- Published: 2026-08-13
- Earliest claimed: 2023-07-27
- Applicants: Wuhan Institute of Virology, Chinese Academy of Sciences
- Inventors: Qinxue HU; Fengfeng NI; Kai HU; Yalan LIU
- Web page: https://patentgrep.com/patent/US20260234663A1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 31/18: for HIV
- C07K 14/34: from Corynebacterium (G)
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/861: Adenoviral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/10341: Use of virus, viral particle or viral elements as a vector
- C12N 2840/203: having an IRES
- C12R 2001/91: Cell lines {; Processes using cell lines}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Provided is a recombinant viral vector, which includes a viral vector as a backbone vector. The viral vector includes five elements of HIV-1-LTR, ELA, IRES, EIB, and DTA, and the HIV-1-LTR element is at 5′ end of remaining four elements. The recombinant viral vector can be used to specifically and efficiently transfer DTA into target cells, and when the target cells are not infected with HIV-1, DTA is not induced and produced.

## Claims

### Claim 1

A recombinant viral vector comprising a viral vector as a backbone vector, wherein the viral vector comprises five elements consisting of HIV-1-LTR, E1A, IRES, E1B, and DTA, and the HIV-1-LTR element is at 5′ end of remaining four elements.

### Claim 2 (depends on 1)

The recombinant viral vector of claim 1, wherein the elements are sequentially arranged on the backbone vector as HIV-1-LTR, E1A, IRES, E1B, and DTA from 5′ end to 3′ end.

### Claim 3 (depends on 2)

The recombinant viral vector of claim 2, wherein nucleotide sequences of HIV-1-LTR, E1A, IRES, E1B, and DTA are as shown in SEQ ID NOs. 1 to 5, respectively.

### Claim 4 (depends on 2)

The recombinant viral vector of claim 2, wherein the vector is an Ad5/F35 adenoviral vector.

### Claim 5 (depends on 2)

The recombinant viral vector of claim 2, wherein a nucleotide sequence of the vector is as shown in SEQ ID NO. 7.

### Claim 6 (depends on 1)

A composition for treating HIV-1 infection comprising the recombinant viral vector of claim 1, and a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

A recombinant virus comprising a recombinant virus prepared with the recombinant viral vector of claim 1.

### Claim 8 (depends on 1)

Use of the recombinant viral vector of claim 1 in the preparation of a composition for the treatment of HIV-1 infection.

### Claim 9 (depends on 8)

A kit for treating HIV-1 infection comprising the composition of claim 8.

### Claim 10 (depends on 9)

The kit of claim 9, wherein the kit further comprises other inhibitors for inhibiting HIV-1.

### Claim 11 (depends on 6)

Use of the composition of claim 6 in the preparation of a composition for the treatment of HIV-1 infection.

### Claim 12 (depends on 8)

A method for treating HIV-1 infection, comprising an operation of administering to a subject the composition of claim 8.
